Product Highlight - Clipax

• First-line chemotherapy of ovarian cancer, CLIPAX is indicated for the treatment of patients with advanced disease or residual disease (>1 cm) after initial laparotomy, in combination with Cisplatin.

• Second line chemotherapy of ovarian cancer, CLIPAX is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy.

• In the adjuvant setting, CLIPAX is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and Cyclophosphamide (AC) therapy.

• CLIPAX in combination with Cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy.



Reference:
Clipax Full Prescribing Information.